Hung‐Chun Chen

7.7k citations
261 papers · 6.2k · 2 hit papers · h-index 42

Impact in

  • Nephrology top 0.2%
    • Chronic Kidney Disease and Diabetes
    • Dialysis and Renal Disease Management
    • Renal Diseases and Glomerulopathies
    • Parathyroid Disorders and Treatments
    • Advanced Glycation End Products research

Papers in

    • Chronic Kidney Disease and Diabetes 71
    • Dialysis and Renal Disease Management 47
    • Renal Diseases and Glomerulopathies 29
    • Parathyroid Disorders and Treatments 13
    • Cardiovascular Health and Disease Prevention 21
    • Cardiovascular Function and Risk Factors 14

Hung‐Chun Chen

258 papers receiving 5.9k citations

Hung‐Chun Chen's Hit Papers

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial 2023 · 195 citations
1950+1+2Years since publication50100150

Peers

Hung‐Chun Chen
Comparison fields: 5 of 134
  • Nephrology 2.8k
  • Clinical Biochemistry 216
  • Cardiology and Cardiovascular Medicine 873
  • Hepatology 296
  • Endocrinology, Diabetes and Metabolism 241
Replace Vassilios Liakopoulos with:
Vassilios Liakopoulos Greece
Seung Hyeok Han South Korea
Kuan‐Yu Hung Taiwan
Ciro Esposito Italy
tae-hyun yoo South Korea
Kevin D. Burns Canada
Shin‐Wook Kang South Korea
Lorenzo Arcangelo Calò Italy
Rafael Selgas Spain
Anton C. Schoolwerth United States
Hung‐Chun Chen relative to Vassilios Liakopoulos Greece Vassilios Liakopoulos's profile →
Citations per field
00.5×2×3×3.9×
Vassilios Liakopoulos · 1×
Citations per year

Countries citing papers authored by Hung‐Chun Chen

Since Specialization
Citations

This map shows the geographic impact of Hung‐Chun Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hung‐Chun Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hung‐Chun Chen more than expected).

Fields of papers citing papers by Hung‐Chun Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hung‐Chun Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hung‐Chun Chen. The network helps show where Hung‐Chun Chen may publish in the future.

Co-authors

The 25 scholars most cited alongside Hung‐Chun Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hung‐Chun Chen Line = papers co-authored together Hung‐Chun Chen links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 261 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
Hit paper breakdown →
2023195
2 2001192
3 2012163
4
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
Hit paper breakdown →
2023163
5 2014133
6 2012120
7 2014102
8 201198
9 201398
10 201094
11 201188
12 201384
13 200079
14 200879
15 200476
16 200070
17 200270
18 199969
19 201466
20 200762

About Hung‐Chun Chen

Hung‐Chun Chen is a scholar working on Nephrology, Cardiology and Cardiovascular Medicine, Clinical Biochemistry, Physiology and Surgery, having authored 261 papers that have together received 6.2k indexed citations. Recurring topics across this work include Chronic Kidney Disease and Diabetes (71 papers), Dialysis and Renal Disease Management (47 papers), Renal Diseases and Glomerulopathies (29 papers), Cardiovascular Health and Disease Prevention (21 papers), Cardiovascular Function and Risk Factors (14 papers), Parathyroid Disorders and Treatments (13 papers), Peripheral Artery Disease Management (12 papers) and Advanced Glycation End Products research (8 papers). The work is most often cited by research in Nephrology (2.8k citations), Clinical Biochemistry (216 citations), Cardiology and Cardiovascular Medicine (873 citations), Hepatology (296 citations) and Endocrinology, Diabetes and Metabolism (241 citations). Hung‐Chun Chen has collaborated with scholars based in Taiwan, United States and Japan. Frequent co-authors include Shang‐Jyh Hwang, Jer‐Ming Chang, Jinn‐Yuh Guh, Chi‐Chih Hung, Szu‐Chia Chen, Yi‐Wen Chiu, Jer‐Chia Tsai, Mei‐Chuan Kuo, Ming‐Yen Lin and Yung‐Hsiung Lai. Their work appears in journals such as PLoS ONE, Scientific Reports, American Journal of Kidney Diseases, Clinical Journal of the American Society of Nephrology and The American Journal of the Medical Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact